Citius Oncology, Inc.
$0.92
▲
8.47%
2026-04-21 06:17:00
NCM: CTOR
Explore Citius Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$77.5 M
Current Price
$0.92
52W High / Low
$6.19 / $0.49
Stock P/E
—
Book Value
$0.69
Dividend Yield
—
ROCE
-45.72%
ROE
-47.41%
Face Value
—
EPS
$-0.31
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
—
Beta
3.43
Debt / Equity
6.51
Current Ratio
0.83
Quick Ratio
0.11
Forward P/E
—
Price / Sales
15.11
Enterprise Value
$56.09 M
EV / EBITDA
—
EV / Revenue
14.22
Rating
None
Target Price
$6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Supernus Pharmaceuticals, Inc. | $51.25 | — | $2.92 B | — | -3.31% | -3.68% | $59.68 / $29.16 | $18.48 |
| 2. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 3. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 4. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
| 5. | Journey Medical Corporation | $5.19 | — | $147.31 M | — | -14.3% | -44.03% | $9.55 / $4.31 | $1.17 |
| 6. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
| 7. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 3.94 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -4.68 M | -4.71 M | -4.94 M | -7.47 M | -6.39 M |
| Net Profit | -5.53 M | -5 M | -5.37 M | -7.74 M | -6.66 M |
| EPS in Rs | -0.06 | -0.06 | -0.06 | -0.09 | -0.08 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -23.52 M | -20.57 M | -12.12 M | -4.86 M |
| Net Profit | -24.76 M | -21.15 M | -12.7 M | -5.43 M |
| EPS in Rs | -0.28 | -0.24 | -0.14 | -0.06 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 100.94 M | 84.37 M | 47.73 M | 42.69 M |
| Total Liabilities | 56.08 M | 38.23 M | 22.2 M | 6.42 M |
| Equity | 44.87 M | 46.14 M | 25.54 M | 36.27 M |
| Current Assets | 27.54 M | 10.97 M | 7.73 M | 2.69 M |
| Current Liabilities | 49.49 M | 32.7 M | 21.05 M | 5.85 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.49 M | 0.13 M | 0 M | 0 M |
| Investing CF | -5.75 M | -5 M | 0 M | — |
| Financing CF | 15.17 M | 4.87 M | 0 M | — |
| Free CF | -11.24 M | -4.87 M | 0 M | 0 M |
| Capex | -5.75 M | -5 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -17.08% | -66.56% | -133.72% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.